SCHEMBL26624006

SCHEMBL26624006

CC1(C)OC(=O)c2ccc(Nc3nc(Nc4ccc5c(c4)CCNC5)ncc3Cl)cc21

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 5/20 0.52
MET P08581 3/20 0.51
ALK Q9UM73 3/20 0.51
BTK Q06187 2/20 0.49
AXL P30530 6/20 0.48
TYRO3 Q06418 6/20 0.48
MERTK Q12866 6/20 0.48
MAP4K1 Q92918 3/20 0.46
MAP4K3 Q8IVH8 2/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
IGF1R P08069 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642937 1.00 WEE1 (0.52) WEE1METALKBTKAXL
SCHEMBL26624018 0.93 MET (0.53) WEE1METALKBTKAXL
SCHEMBL31448272 0.87 MAP4K1 (0.56) MAP4K1MAP4K3IRAK4
SCHEMBL26624021 0.87 MAP4K1 (0.56) MAP4K1MAP4K3IRAK4
SCHEMBL31442213 0.83 WEE1 (0.48) WEE1METALKBTKAXL
SCHEMBL30642959 0.82 BTK (0.50) WEE1METALKBTKAXL
SCHEMBL31442105 0.82 WEE1 (0.52) WEE1METALKBTKAXL
SCHEMBL31442100 0.81 AXL (0.53) WEE1METALKBTKAXL
SCHEMBL31442144 0.80 MET (0.53) WEE1METALKBTKAXL
SCHEMBL30642956 0.79 TYRO3 (0.55) ALKBTKAXLTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015340-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-15 US claimed
EP-4520757-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2025-03-12 EP claimed
WO-2023214772-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER 한국화학연구원 2023-11-09 WO claimed
US-20260015340-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-15 US disclosed
EP-4520757-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2025-03-12 EP disclosed
WO-2023214772-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER 한국화학연구원 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015340-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER MINK1, HK1, PDK3 WEE1 50/4885MET 366/4885ALK 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.